Integrative Analysis of Pulmonary Sarcomatoid Carcinoma (PSC)
NCT ID: NCT04215913
Last Updated: 2020-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
300 participants
OBSERVATIONAL
2019-12-30
2025-12-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Liquid Biopsy in Advanced Oligometastatic NSCLC Receiving Surgery
NCT05648370
Integrative Analysis of Large-cell Lung Cancer
NCT02917369
Identification of a Plasma Proteomic Signature for Lung Cancer
NCT01752101
Genotyping of Non-small Cell Lung Cancer
NCT02002117
Multicenter Observational Study of Advanced Non-small Cell Lung Cancer With Malignant Pleural Effusion
NCT04263688
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normal lung tissue
Normal lung tissue from PSC patients
The investigators will extract total protein, DNA and RNA from PSC patients.
The investigators will extract total protein, DNA and RNA from PSC patients.
PSC tissues
PSC tissues from PSC patients
The investigators will extract total protein, DNA and RNA from PSC patients.
The investigators will extract total protein, DNA and RNA from PSC patients.
Metastasis tissues
Metastasis tissues from PSC patients
The investigators will extract total protein, DNA and RNA from PSC patients.
The investigators will extract total protein, DNA and RNA from PSC patients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The investigators will extract total protein, DNA and RNA from PSC patients.
The investigators will extract total protein, DNA and RNA from PSC patients.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No severe major organ dysfunction
* World Health Organization (WHO) performance status of 0 or 1
* No prior cancer chemotherapy
Exclusion Criteria
* Severe major organ dysfunction
* WHO performance status of \>1
* Prior cancer chemotherapy
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China
OTHER
Anhui Medical University
OTHER
Shanghai 10th People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Da Fu
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Da Fu
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Boland JM, Mansfield AS, Roden AC. Pulmonary sarcomatoid carcinoma-a new hope. Ann Oncol. 2017 Jul 1;28(7):1417-1418. doi: 10.1093/annonc/mdx276. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FD52Rainy
Identifier Type: REGISTRY
Identifier Source: secondary_id
2019-FD52Rainy-PSC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.